Drug Study in Pediatric Subjects With Migraines

This study has been completed.

Study NCT00604812 Information provided by Merck

First Received: October 17, 2007 Last Updated: September 2, 2009 History of Changes

Study Type:	Interventional
Study Design:	Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment
Condition:	Migraine Disorders
Interventions:	Drug: rizatriptan benzoate (5 mg) Drug: rizatriptan benzoate (10 mg) Drug: Comparator: Placebo

Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Panel A - 5 mg Rizatriptan	Rizatriptan 5 mg once orally
Panel A - Placebo	Placebo closely matching 5 mg rizatriptan once orally
Panel B - 10 mg Rizatriptan	Rizatriptan 10 mg once orally
Panel B - Placebo	Placebo exactly matching 10 mg rizatriptan once orally

Participant Flow: Overall Study

	Panel A - 5 mg Rizatriptan	Panel A - Placebo	Panel B - 10 mg Rizatriptan	Panel B - Placebo
STARTED	9	3	10	3
COMPLETED	9	3	10	3
NOT COMPLETED	0	0	0	0

Baseline Characteristics

Outcome Measures

1. Primary:

Safety and Tolerability of Single Doses of Rizatriptan in Pediatric Migraineurs [ 24 Hours ]

Show Outcome Measure 1

2. Secondary:

Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan- Area Under the Curve (AUC(0-∞)) [ 24 Hours ]

Show Outcome Measure 2

3. Secondary:

Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan – Maximum Concentration (Cmax) [ 24 Hours ]

Show Outcome Measure 3

4. Secondary:

Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan – Time to Maximum Concentration (Tmax) [ 24 Hours ]

Show Outcome Measure 4

5. Secondary:

Preliminary Pharmacokinetic Data Following Single Dose Administration of Rizatriptan – Apparent Half-life (Apparent t½) [ 24 Hours ]

Show Outcome Measure 5

Serious Adverse Events

Other Adverse Events

More Information

Certain Agreements:

All Principal Investigators ARE employed by the organization sponsoring the study.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Pharmacokinetic data presented are preliminary data.

Results Point of Contact:

Name/Title: Executive Vice President, Clinical and Quantitative Sciences
Organization: Merck & Co., Inc.
phone: 1-800-672-6372

No publications provided

Responsible Party:	Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences )
Study ID Numbers:	2007_601, MK0462-083
Study First Received:	October 17, 2007
Results First Received:	June 3, 2009
Last Updated:	September 2, 2009
ClinicalTrials.gov Identifier:	NCT00604812 History of Changes
Health Authority:	United States: Food and Drug Administration